Endocrinology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Endocrinology Search

Endocrinology

Endocrinology

Home News Diseases Conferences Special Reports Multimedia

Statins do not prevent CV events, mortality in old patients without T2D

Stephen Padilla, 15 hours ago

Statin treatment does not appear to reduce atherosclerotic cardiovascular disease (CVD) or all-cause mortality in patients without type 2 diabetes (T2D) aged ≥75 years, even when the incidence of atherosclerotic CVD is significantly higher than the risk thresholds proposed for statin use, according to a recent study.

Dietary, physical activity counselling does not confer benefits for gestational diabetes

Yesterday

A lifestyle intervention combining dietary and physical activity counselling initiated during early pregnancy does not appear to effectively improve dietary intake, physical activity, or obstetric and perinatal outcomes in pregnant women at high risk of gestational diabetes mellitus, according to data from the RADIEL trial.

Drinking green tea may increase risk of type 2 diabetes in Chinese adults

2 days ago

Green tea consumption is associated with an increased risk of type 2 diabetes, and this association shows a dose-response pattern, according to the results of two large-scale population-based cohorts of Chinese men and women.

Anaemia pre-surgery may affect QoL after hip replacement

Roshini Claire Anthony, 5 days ago

Elderly patients who undergo hip replacement surgery may have poorer health-related quality of life (HRQoL) outcomes if they had anaemia prior to the surgery, according to a study from Singapore.

Family history of diabetes linked to heightened risk of colorectal cancer in men

6 days ago

Family history of diabetes appears to pose an increased risk of colorectal cancer in men, and this association may be partly mediated by altered sex hormones and adiponectin, according to a recent study.

Redefining diabetes management: Combining glycaemic control with cardiovascular protection to deliver better patient outcomes

31 May 2018

At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.

Optimizing hormone replacement therapy in menopause

05 Apr 2017

At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.

The Future of Osteoporosis Management

20 Jan 2017

At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.

Role of gliclazide MR today: Efficacy and safety you can trust

04 Jan 2017

At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).

Preventing 3 key heart failure risk factors in midlife may prolong disease-free survival

Pearl Toh, 07 Dec 2016

Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.

Dual-hormone artificial pancreas beats insulin-alone system in glycaemic control in small study

Pearl Toh, 10 Jul 2018

A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.

Sotagliflozin sustains HbA1c reductions, improves outcomes over 1 year in T1D

Roshini Claire Anthony, 10 Jul 2018

Combining the dual sodium glucose cotransporter (SGLT) 1 and 2 inhibitor sotagliflozin with optimized insulin therapy led to sustained reductions in HbA_1c levels over 1 year in adults with type 1 diabetes (T1D), according to a study presented at ADA 2018.

Exenatide-dapagliflozin efficacy for T2D persists for 2 years

Elvira Manzano, 06 Jul 2018

Combined treatment with the GLP-1 receptor agonist exenatide and the SGLT-2 inhibitor dapagliflozin appeared to be effective up to 2 years in patients with type 2 diabetes (T2D), the phase III DURATION-8 extension trial has shown.

No increased risk of below-knee amputation with canagliflozin

Roshini Claire Anthony, 05 Jul 2018

The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!